Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC): a randomised superiority trial (MRC COIN)

Номзүйн дэлгэрэнгүй
Үндсэн зохиолчид:	Maughan, T, Adams, R, Smith, C, Seymour, M, Wilson, R, Meade, A, Fisher, D, Madi, A, Cheadle, J, Kaplan, R
Формат:	Journal article
Хэвлэсэн:	2009

ADDITION OF CETUXIMAB TO OXALIPLATIN-BASED COMBINATION CHEMOTHERAPY (CT) IN PATIENTS WITH K-ras WILD-TYPE ADVANCED COLORECTAL CANCER (ACRC): EFFECTS ON OVERALL SURVIVAL. MRC COIN (CR10) TRIAL RESULTS
-н: Adams, R, зэрэг
Хэвлэсэн: (2009)

THE ADDITION OF CETUXIMAB TO OXALIPLATIN-FLUOROPYRIMIDINE CHEMOTHERAPY IN FIRST-LINE ADVANCED COLORECTAL CANCER IN THE MRC COIN TRIAL: IDENTIFICATION OF POTENTIALLY RESPONSIVE SUBSETS OF PATIENTS
-н: Maughan, T, зэрэг
Хэвлэсэн: (2010)

Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience.
-н: Adams, R, зэрэг
Хэвлэсэн: (2009)

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
-н: Maughan, T, зэрэг
Хэвлэсэн: (2011)

Intermittent Chemotherapy (CT) Plus Continuous or Intermittent Cetuximab (C) in the First-line Treatment of Advanced Colorectal Cancer (aCRC): Results of the Two-arm Phase II Randomised MRC COIN-B Trial
-н: Wasan, H, зэрэг
Хэвлэсэн: (2011)

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial.
-н: Madi, A, зэрэг
Хэвлэсэн: (2012)

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: The MRC COIN trial
-н: Madi, A, зэрэг
Хэвлэсэн: (2012)

THROMBOCYTOSIS AS A PREDICTIVE AND PROGNOSTIC MARKER IN ADVANCED COLORECTAL CANCER (ACRC): RESULTS OF THE MRC COIN TRIAL EXPLORED
-н: Maughan, T, зэрэг
Хэвлэсэн: (2010)

Intermittent versus continuous oxaliplatin-based combination chemotherapy in patients with advanced colorectal cancer: a randomised non-inferiority trial (MRC COIN)
-н: Adams, R, зэрэг
Хэвлэсэн: (2009)

THE IMPACT OF MILD RENAL IMPAIRMENT ON THE TOXICITY OF OXALIPLATIN AND FLUOROPYRIMIDINE REGIMENS: EXPERIENCE IN THE MRC COIN TRIAL
-н: Madi, A, зэрэг
Хэвлэсэн: (2010)

INTERMITTENT VS. CONTINUOUS OXALIPLATIN-FLUOROPYRIMIDINE CHEMOTHERAPY IN THE MRC COIN TRIAL IN ADVANCED COLORECTAL CANCER: UPDATED EFFICACY RESULTS, QUALITY OF LIFE AND POTENTIAL PREDICTIVE FACTORS
-н: Adams, R, зэрэг
Хэвлэсэн: (2010)

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
-н: Adams, R, зэрэг
Хэвлэсэн: (2011)

Cetuximab therapy in first-line metastatic colorectal cancer and intermittent palliative chemotherapy: review of the COIN trial.
-н: Adams, R, зэрэг
Хэвлэсэн: (2008)

CETUXIMAB COMBINED WITH INFUSIONAL 5-FLUOROURACIL/FOLINIC ACID AND OXALIPLATIN IN METASTATIC COLORECTAL CANCER: POOLED ANALYSIS OF COIN AND OPUS STUDY DATA
-н: Taieb, J, зэрэг
Хэвлэсэн: (2012)

Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab.
-н: Smith, C, зэрэг
Хэвлэсэн: (2013)

Cetuximab plus Irinotecan as third line chemotherapy for metastatic colorectal cancer
-н: Moe, M, зэрэг
Хэвлэсэн: (2008)

Comprehensive pharmacogenetic profiling of the epidermal growth factor receptor pathway for biomarkers of response to, and toxicity from, cetuximab
-н: Madi, A, зэрэг
Хэвлэсэн: (2017)

HIGH THROUGHPUT SOMATIC PROFILING OF THE RAS-RAF-MAP AND PI3K-PTEN-AKT PATHWAYS IN ADVANCED COLORECTAL CANCER AND CORRELATIONS WITH RESPONSE TO CETUXIMAB
-н: Smith, C, зэрэг
Хэвлэсэн: (2010)

Chemotherapy-free intervals for patients with metastatic colorectal cancer remain an option.
-н: Maughan, T, зэрэг
Хэвлэсэн: (2010)

Chemotherapy choices and doses in frail and elderly patients with advanced colorectal cancer: an MRC randomised clinical trial (FOCUS2)
-н: Seymour, M, зэрэг
Хэвлэсэн: (2007)

Triepitopic Antibody Fusions Inhibit Cetuximab-Resistant BRAF and KRAS Mutant Tumors via EGFR Signal Repression
-н: Manzari, Mandana T., зэрэг
Хэвлэсэн: (2014)

A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS (RCTS) OF EGFR-TARGETED MONOCLONAL ANTIBODY (MAB) THERAPY IN ADVANCED COLORECTAL CANCER (ACRC): IMPACT OF K-RAS STATUS
-н: Vale, C, зэрэг
Хэвлэсэн: (2009)

Role for nucleotide-excision repair gene variants in oxaliplatin-induced peripheral neuropathy
-н: West, H, зэрэг
Хэвлэсэн: (2018)

Impact of K-ras status on the effects of EGFR-targeted monoclonal antibody (MAb) therapy in advanced colorectal cancer (ACRC): A systematic review and meta-analysis of randomized controlled trials (RCTs)
-н: Vale, C, зэрэг
Хэвлэсэн: (2009)

Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy
-н: Madi, A, зэрэг
Хэвлэсэн: (2018)

Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.
-н: Seymour, M, зэрэг
Хэвлэсэн: (2007)

Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status: a post-hoc analysis of the MRC COIN study.
-н: Wood, G, зэрэг
Хэвлэсэн: (2017)

FOCUS4-D: Results from a randomised, placebo controlled trial (RCT) of AZD8931 (an inhibitor of signalling by HER1, 2, and 3) in patients (pts) with advanced or metastatic colorectal cancer (aCRC) in tumours that are wildtype (wt) for BRAF, PIK3CA, KRAS and NRAS
-н: Adams, R, зэрэг
Хэвлэсэн: (2016)

Superiority and non-inferiority: Two sides of the same coin?
-н: Dunn, D, зэрэг
Хэвлэсэн: (2018)

Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial.
-н: Seymour, M, зэрэг
Хэвлэсэн: (2011)

Cells deficient in the base excision repair protein, DNA polymerase beta, are hypersensitive to oxaliplatin chemotherapy.
-н: Yang, J, зэрэг
Хэвлэсэн: (2010)

Self-assembled oxaliplatin(IV) prodrug-porphyrin conjugate for combinational photodynamic therapy and chemotherapy
-н: Lim, Wei Qi, зэрэг
Хэвлэсэн: (2021)

Pattern recognition receptor polymorphisms as predictors of oxaliplatin benefit in colorectal cancer
-н: Gray, V, зэрэг
Хэвлэсэн: (2019)

Tumour expression of the DNA repair protein, XPF, predicts pathological response to neoadjuvant oxaliplatin chemotherapy in oesophageal cancer
-н: Gillies, R, зэрэг
Хэвлэсэн: (2011)

Capecitabine (X) and oxaliplatin (O) combination chemotherapy in patients (pts) with advanced gall bladder or biliary tract cancer: A phase II study
-н: Evans, T, зэрэг
Хэвлэсэн: (2006)

A pilot study of the use of Oxaliplatin in metastatic colorectal cancer at Velindre
-н: Mitra, S, зэрэг
Хэвлэсэн: (2001)

XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: Suitability as a biomarker for patient selection
-н: Hatch, S, зэрэг
Хэвлэсэн: (2014)

XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: suitability as a biomarker for patient selection.
-н: Hatch, S, зэрэг
Хэвлэсэн: (2014)

Design and development of information portal for Asian Communication Resource Centre (ACRC).
-н: Yohanes Ramli.
Хэвлэсэн: (2008)

NEOSCOPE: A randomised phase II study of induction chemotherapy followed by oxaliplatin/capecitabine or carboplatin/paclitaxel based pre-operative chemoradiation for resectable oesophageal adenocarcinoma
-н: Mukherjee, S, зэрэг
Хэвлэсэн: (2017)

Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC): a randomised superiority trial (MRC COIN)

Ижил төстэй зүйлс

Ижил төстэй зүйлс